Ventyx biosciences reports fourth quarter and full year 2024 financial results and highlights recent corporate progress

Topline data readouts from multiple phase 2 studies expected throughout 2025 vtx2735 in patients with recurrent pericarditis in h2 vtx3232 in participants with obesity and cardiometabolic risk factors in h2 vtx3232 biomarker study in patients with early parkinson's disease in q2 cash, cash equivalents and marketable securities balance of $252.9m as of december 31, 2024 expected to fund operations into at least h2 2026 san diego, feb. 27, 2025 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”, “company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “heading into 2025, ventyx has established itself as the leader in the field of nlrp3 inhibition having progressed two novel inhibitors, vtx3232 and vtx2735, into phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications.
VTYX Ratings Summary
VTYX Quant Ranking